Articles From: Merck to buy Cubist Pharmaceuticals for $8.4 billion to Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity


2014/12/8
By Peter Loftus and Dana CimillucaThe per-share bid of $102 is 37% above Friday's closing price of Cubist's stock Drug giant Merck & Co.
Sign-up for Merck to buy Cubist Pharmaceuticals for $8.4 billion investment picks
2014/12/8
HOUSTON, Dec.
Sign-up for Midstates Petroleum Announces Termination of DeQuincy Assets Sales Agreement investment picks
2014/12/8
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163558&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Mizuho Securities USA Announces New Equity Capital Markets Head investment picks
2014/12/8
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has cleared a labeling update for the Prosigna ® Breast Cancer Gene Signature Assay.
Sign-up for NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis investment picks
2014/12/8
LANSING, Mich.
Sign-up for Neogen acquires assets of its Chinese distributor investment picks
2014/12/8
http://www.marketwire.com/library/MwGo/2014/12/8/11G028090/NeuLion,_Inc.-729822400065.jpg PLAINVIEW, NY--(Marketwired - December 08, 2014) - NeuLion, Inc. (TSX: NLN), the leading enabler and provider of live and on-demand content to Internet-connected devices, has been selected to power the digital extension of the TV of Tomorrow Show on December 9, 2014 in New York City.
Sign-up for NeuLion Selected to Power TV of Tomorrow investment picks
2014/12/8
Study is the First to Evaluate Investigational Combination of an Oncolytic Immunotherapy and Anti-PD-1 Therapy THOUSAND OAKS, Calif.
Sign-up for New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma investment picks
2014/12/8
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163419&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for Oracle's New Cloud Development Center in Canada Reiterates Company's Commitment to Cloud Innovation investment picks
2014/12/8
http://www.ccnmatthews.com/logos/20071206-painted%20pony%20big.png CALGARY, ALBERTA --
Sign-up for Painted Pony Announces 2015 Capital Expenditure Program and Increased Credit Facilities investment picks
2014/12/8
DENVER, December 8, 2014 (GLOBE NEWSWIRE) -- PDC Energy, Inc. ("PDC," the "Company," "we" or "us") (Nasdaq:PDCE) today announced its capital budget and production guidance for 2015.
Sign-up for PDC Energy Announces 2015 Capital Budget of $557 Million and Production Guidance of 13.8 to 14.5 Million Boe or Approximately 50% Year-Over-Year Growth While Maintaining Its Strong Financial Position investment picks
2014/12/8
Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.
Sign-up for Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform investment picks
2014/12/8
OLNEY, Md., Dec.
Sign-up for Photo Release -- Sandy Spring Bank Opens New Bethesda Community Office investment picks
2014/12/8
SPOKANE, Wash., Dec.
Sign-up for Potlatch Completes Timberland Acquisition and Board Increases Dividend 7% investment picks
2014/12/8
ORLANDO, Fla., Dec.
Sign-up for Power Solutions International Launches Newly Designed 4.3-Liter and 180kW 8.8-Liter Engines at POWER-GEN investment picks
2014/12/8
http://media3.marketwire.com/logos/20120511-Precision145.jpg CALGARY, ALBERTA --
Sign-up for Precision Drilling Corporation Announces 2015 Capital Expenditure Plan and Asset Divestiture investment picks
2014/12/8
Michael Bayley named CEO of Royal Caribbean International; Lisa Lutoff-Perlo appointed CEO of Celebrity Cruises MIAMI , Dec.
Sign-up for Proven Veterans Named To Lead The Largest Lines At Royal Caribbean Cruises Ltd. investment picks
2014/12/8
PTS, Inc. (OTC Pinksheets: PTSH) announced today that it is finalizing a Letter of Intent to acquire KC 9000, a proprietary technology owned by Freedom Energy Holdings, Inc. (Pinksheets: FDMF) Under the terms of the agreement, the ownership of KC 9000 will be transferred to a newly formed subsidiary and PTSH will acquire the subsidiary for an undisclosed amount of stock.
Sign-up for PTS, Inc Announces New Business Relationship with KC 9000 investment picks
2014/12/8
Allied nations fire missiles from air and ground near Arctic Circle VIDSEL TEST RANGE, Sweden , Dec.
Sign-up for Raytheon AMRAAM® and NASAMS showcased in Thor's Hammer exercise investment picks
2014/12/8
ORLANDO, Fla.
Sign-up for Raytheon named one of America's most community-minded companies by The Civic 50 investment picks
2014/12/8
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163457&ProfileId=051205&sourceType=1 OAKS, PA --
Sign-up for SEI Introduces AIFMD Annex IV Reporting Solution to Help Alternative Managers Meet New Transparency Rules investment picks
2014/12/8
Silicon Labs (NASDAQ: SLAB), a leading provider of broadcast video solutions for the television market, today introduced its next-generation digital TV demodulator family offering expanded support for the latest satellite, terrestrial and cable standards.
Sign-up for Silicon Labs Debuts Next-Generation Demodulator Portfolio for Digital Television Market investment picks
2014/12/8
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, will present data from 16 clinical research programs at the upcoming North American Neuromodulation Society (NANS) meeting in Las Vegas, Nevada, December 11 – 14, 2014.
Sign-up for St. Jude Medical to Present Data from 16 Research Abstracts and Highlight Its Product Portfolio at the 2014 North American Neuromodulation Society Meeting investment picks
2014/12/8
State Street Global Advisors (SSGA), the asset management arm of State Street Corporation (NYSE: STT), today announced that its global market outlook for 2015 anticipates that diverging global monetary policy will have an impact on every asset class, but poses interesting and diverse opportunities for proactive investors.
Sign-up for State Street Global Advisors: A Divergent World Creates Opportunities in 2015 investment picks
2014/12/8
LAFAYETTE, La., Dec.
Sign-up for Stone Energy Corporation Announces Successful Utica Shale Exploration Well investment picks
2014/12/8
Strategic Global Income Fund, Inc. (the "Fund") (NYSE:SGL), a non-diversified, closed-end management investment company seeking a high level of current income as a primary objective and capital appreciation as a secondary objective through investments in US and foreign debt securities, today announced that the Fund’s Board of Directors declared a regular monthly distribution of $0.0422 per share.
Sign-up for Strategic Global Income Fund, Inc. – Distribution Declaration and Updated Price & Distribution Rate Information investment picks
2014/12/8
FDA Clearance for NS3000, a 30 Watt Holmium Laser for the Urology Market ROSEVILLE, Calif.
Sign-up for Syneron Candela Signs Agreement with American Medical Systems to Supply Holmium Laser for Urology investment picks
2014/12/8
TD Ameritrade, Inc. (“TD Ameritrade”), a broker-dealer subsidiary of TD Ameritrade Holding Corporation (NYSE:AMTD), is today releasing the Investor Movement Index ® reading for November 2014.
Sign-up for TD Ameritrade’s Investor Movement Index: IMX Double Dips in November investment picks
2014/12/8
MENLO PARK, Calif.
Sign-up for The Institute of Internal Auditors Research Foundation Selects Protiviti as Partner for 2015 Stakeholder Study investment picks
2014/12/8
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163664&ProfileId=051205&sourceType=1 DENVER, CO --
Sign-up for Thompson Creek Metals Company Announces Change in Senior Management investment picks
2014/12/8
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data demonstrating that its comprehensive genomic profile, FoundationOne® Heme , identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent 1 .
Sign-up for Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Merck to buy Cubist Pharmaceuticals for $8.4 billion to Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent